📰 Ted Human Effector News
Ted Human Effector News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Ted Human Effector. Real-time updates on events, politics, business and more.
May 23, 2024
Oral presentation in "Developmental Therapeutics-Immunotherapy" session on Sunday, June 2, 2024, at 11:30 AM CDT CatalYm today announced that positive new follow-up results from its ongoing "GDFATHER"
May 25, 2023
Oral presentation in "Developmental Therapeutics-Immunotherapy" session on Sunday, June 4 at 9:45 AM CDT CatalYm today announced that the first results from its ongoing Phase 2a trial "GDFATHER-2"
November 22, 2022
Jeito Capital co-leads EUR 50 million financing in CatalYm, a clinical-stage biopharma company developing novel immunotherapies for
November 22, 2022
CatalYmtoday announced the close of a EUR 50 million (USD 49 million) Series C financing round. The oversubscribed round was co-led by new investors, Brandon Capital and Jeito Capital with participation
September 10, 2022
In an oral presentation at ESMO 2022, data from the GDFATHER-1 trial showed that treatment with visugromab and the anti-PD-1 inhibitor nivolumab resulted in excellent tolerability and significant anti-tumor
March 1, 2022
CatalYm receives International Nonproprietary Name (INN) visugromab for CTL-002 as approved by the World Health Organization CatalYm today announced treatment of the first patients in a series of